SY-LB-35

SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt , ERK , p38 and JNK intracellular signaling pathways In Vitro SY-LB-35 (0.01-1000 μM; 24 h) stimulates significant increases in cell number and cell viability in the C2C12 myoblast cell line. SY-LB-35 (0.01-10 μM; 30 min or 15 min) stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulates the phosphorylation and activation of PI3K in the C2C12 cells. SY-LB-35 (0.01-10 μM; 24 h) causes the cell cycle shifting to S and G2/M phases in the C2C12 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: C2C12 cells Concentration: 0.01, 0.1, 1, 10, 100 and 1000 μM Incubation Time: 24 h Result: Stimulated significant increases in cell number and cell viability. Western Blot AnalysisCell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 30 or 15 min Result: Stimulated Smad phosphorylation and nuclear translocation, activated the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulated the phosphorylation and activation of PI3K in the C2C12 cells. Cell Cycle AnalysisCell Line: C2C12 cells Concentration: 0.01, 0.1, 1 and 10 μM Incubation Time: 24 h Result: Caused the cell cycle shifting to S and G2/M phases. Form:Solid IC50& Target:BMP

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet